{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:04:46Z","timestamp":1792037086522,"version":"4.4.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T00:00:00Z","timestamp":1612483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T00:00:00Z","timestamp":1612483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s10637-021-01076-8","type":"journal-article","created":{"date-parts":[[2021,2,6]],"date-time":"2021-02-06T14:22:40Z","timestamp":1612621360000},"page":"1106-1112","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Phase 2 study of bevacizumab plus carboplatin\/nab-paclitaxel followed by bevacizumab plus nab\u2010paclitaxel for non\u2010squamous non\u2010small cell lung cancer with malignant pleural effusion"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6529-3092","authenticated-orcid":false,"given":"Motohiro","family":"Tamiya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Tamiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidekazu","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiko","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanako","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shojiro","family":"Minomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Nakao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinobu","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujiro","family":"Naito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Shiroyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoichi","family":"Okishio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Kumagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Atagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumio","family":"Imamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Hirashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,5]]},"reference":[{"key":"1076_CR1","first-page":"47","volume":"3","author":"S Sugiura","year":"1997","unstructured":"Sugiura S, Ando Y, Minami H, Ando M, Sakai S, Shimokata K (1997) Prognostic value of pleural effusion in patients with non-small cell lung cancer. Clin Cancer Res 3:47\u201350","journal-title":"Clin Cancer Res"},{"key":"1076_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2010.136994","author":"ME Roberts","year":"2010","unstructured":"Roberts ME, Neville E, Berrisford RG, Antunes G, Ali NJ (2010) Management of a malignant pleural effusion: British Thoracic Society Pleural Disease Guideline 2010. Thorax 65(Suppl 2):ii32\u2013i40. https:\/\/doi.org\/10.1136\/thx.2010.136994"},{"key":"1076_CR3","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.lungcan.2007.07.009","volume":"58","author":"K Yoshida","year":"2007","unstructured":"Yoshida K, Sugiura T, Takifuji N, Kawahara M, Matsui K, Kudoh S, Takada M, Fukuoka M, Ariyoshi Y, Fukuda H, Saijo N (2007) Randomized phase II trial of three intrapleural therapy regimens for the management of malignant pleural effusion in previously untreated non-small cell lung cancer: JCOG 9515. Lung Cancer 58:362\u2013368. https:\/\/doi.org\/10.1016\/j.lungcan.2007.07.009","journal-title":"Lung Cancer"},{"key":"1076_CR4","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1093\/jjco\/hyy020","volume":"48","author":"H Saka","year":"2018","unstructured":"Saka H, Oki M, Kitagawa C, Kogure Y, Kojima Y, Saito AM, Ishida A, Miyazawa T, Takeda K, Nakagawa K, Sasada S (2018) Sterilized talc pleurodesis for malignant pleural effusions: a phase II study for investigational new drug application in Japan. Jpn J Clin Oncol 48:376\u2013381. https:\/\/doi.org\/10.1093\/jjco\/hyy020","journal-title":"Jpn J Clin Oncol"},{"key":"1076_CR5","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa061884","volume":"355","author":"A Sandler","year":"2006","unstructured":"Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542\u20132550. https:\/\/doi.org\/10.1056\/NEJMoa061884","journal-title":"N Engl J Med"},{"key":"1076_CR6","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1200\/JCO.2007.14.5466","volume":"27","author":"M Reck","year":"2009","unstructured":"Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N, Manegold C (2009) Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for non-squamous non-small-cell lung cancer: AVAil. J Clin Oncol 27:1227\u20131234. https:\/\/doi.org\/10.1200\/JCO.2007.14.5466","journal-title":"J Clin Oncol"},{"key":"1076_CR7","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1183\/09031936.05.00037004","volume":"25","author":"U Sack","year":"2005","unstructured":"Sack U, Hoffmann M, Zhao XJ, Chan KS, Hui DSC, Gosse H, Engelmann L, Schauer J, Emmrich F, Hoheisel (2005) G.Vascular endothelial growth factor in pleural effusions of different origin. Eur Respir J 25:600\u2013604. https:\/\/doi.org\/10.1183\/09031936.05.00037004","journal-title":"Eur Respir J"},{"key":"1076_CR8","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1007\/s002620050592","volume":"48","author":"H Yanagawa","year":"1999","unstructured":"Yanagawa H, Takeuchi E, Suzuki Y, Ohmoto Y, Bando H, Sone S (1999) Vascular endothelial growth factor in malignant pleural effusion associated with lung cancer. Cancer Immunol Immunother 48:396\u2013400. https:\/\/doi.org\/10.1007\/s002620050592","journal-title":"Cancer Immunol Immunother"},{"key":"1076_CR9","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1378\/chest.116.3.760","volume":"116","author":"DS Cheng","year":"1999","unstructured":"Cheng DS, Rodriguez RM, Perkett EA, Rogers J, Bienvenu G, Lappalainen U, Light RW (1999) Vascular endothelial growth factor in pleural fluid. Chest 116:760\u2013765. https:\/\/doi.org\/10.1378\/chest.116.3.760","journal-title":"Chest"},{"key":"1076_CR10","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1136\/thx.54.8.707","volume":"54","author":"DR Thickett","year":"1999","unstructured":"Thickett DR, Armstrong L, Millar AB (1999) Vascular endothelial growth factor (VEGF) in inflammatory and malignant pleural effusions. Thorax 54:707\u2013710. https:\/\/doi.org\/10.1136\/thx.54.8.707","journal-title":"Thorax"},{"key":"1076_CR11","doi-asserted-by":"publisher","first-page":"4368","DOI":"10.1200\/JCO.2002.10.088","volume":"20","author":"FD Harold","year":"2002","unstructured":"Harold FD (2002) Vascular permeability factor\/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 20:4368\u20134380. https:\/\/doi.org\/10.1200\/JCO.2002.10.088","journal-title":"J Clin Oncol"},{"key":"1076_CR12","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1007\/s12032-013-0676-7","volume":"30","author":"M Tamiya","year":"2013","unstructured":"Tamiya M, Tamiya A, Yamadori T, Nakao K, Asami K, Yasue T, Otsuka T, Shiroyama T, Morishita N, Suzuki H, Okamoto N (2013) Phase2 study of bevacizumab with carboplatin-paclitaxel for non-small cell lung cancer with malignant pleural effusion. Med Oncol 30:676. https:\/\/doi.org\/10.1007\/s12032-013-0676-7","journal-title":"Med Oncol"},{"key":"1076_CR13","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.lungcan.2016.07.003","volume":"99","author":"K Usui","year":"2016","unstructured":"Usui K, Sugawara S, Nishitsuji M, Fujita Y, Inoue A, Mouri A, Watanabe H, Sakai H, Kinoshita I, Ohhara Y, Maemondo M (2016) A phase II study of bevacizumab with carboplatin-pemetrexed in non-squamous non-small cell lung carcinoma patients with malignant pleural effusions: North East Japan Study Group Trial NEJ013A. Lung. Cancer 99:131\u2013136. https:\/\/doi.org\/10.1016\/j.lungcan.2016.07.003","journal-title":"Cancer"},{"key":"1076_CR14","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L (2000) New Guidelines to Evaluate the Response to Treatment in Solid Tumors. J Natl Cancer Inst 92:205\u2013216. https:\/\/doi.org\/10.1093\/jnci\/92.3.205","journal-title":"J Natl Cancer Inst"},{"key":"1076_CR15","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.lungcan.2011.12.005","volume":"76","author":"S Niho","year":"2012","unstructured":"Niho S, Kunitoh H, Nokihara H, Horai T, Ichinose Y, Hida T, Yamamoto N, Kawahara M, Shinkai T, Nakagawa K, Matsui K (2012) Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer. Lung Cancer 76:362\u2013367. https:\/\/doi.org\/10.1016\/j.lungcan.2011.12.005","journal-title":"Lung Cancer"},{"key":"1076_CR16","doi-asserted-by":"publisher","first-page":"3004","DOI":"10.1200\/JCO.2012.42.3749","volume":"31","author":"F Barlesi","year":"2013","unstructured":"Barlesi F, Scherpereel A, Rittmeyer A, Pazzola A, Ferrer Tur N, Kim JH, Ahn MJ, Aerts JG, Gorbunova V, Vikstr\u00f6m A, Wong EK (2013) Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced non-squamous non-small-cell lung cancer: AVAPERL (MO22089). J Clin Oncol 31:3004\u20133011. https:\/\/doi.org\/10.1200\/JCO.2012.42.3749","journal-title":"J Clin Oncol"},{"key":"1076_CR17","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1200\/JCO.19.01494","volume":"38","author":"T Seto","year":"2020","unstructured":"Seto T, Azuma K, Yamanaka T, Sugawara S, Yoshioka H, Wakuda K, Atagi S, Iwamoto Y, Hayashi H, Okamoto I, Saka H (2020) Randomized Phase III Study of Continuation Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous Non-Small-Cell Lung Cancer: COMPASS (WJOG5610L). J Clin Oncol 38:793\u2013803. https:\/\/doi.org\/10.1200\/JCO.19.01494","journal-title":"J Clin Oncol"},{"key":"1076_CR18","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1200\/JCO.19.01006","volume":"37","author":"SS Ramalingam","year":"2019","unstructured":"Ramalingam SS, Dahlberg SE, Belani CP, Saltzman JN, Pennell NA, Nambudiri GS, McCann JC, Winegarden JD, Kassem MA, Mohamed MK, Rothman JM (2019) Pemetrexed, Bevacizumab, or the Combination As Maintenance Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer: ECOG-ACRIN 5508. J Clin Oncol 37:2360\u20132367. https:\/\/doi.org\/10.1200\/JCO.19.01006","journal-title":"J Clin Oncol"},{"key":"1076_CR19","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1097\/00000421-199808000-00021","volume":"21","author":"A Ohtsu","year":"1998","unstructured":"Ohtsu A, Boku N, Tamura F, Muro K, Shimada Y, Saigenji K, Akazawa S, Kitajima M, Kanamaru R, Taguchi T (1998) An early phase II study of a 3-hour infusion of paclitaxel for advanced gastric cancer. Am J Clin Oncol 21:416\u2013419. https:\/\/doi.org\/10.1097\/00000421-199808000-00021","journal-title":"Am J Clin Oncol"},{"key":"1076_CR20","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s10120-005-0351-6","volume":"9","author":"S Hironaka","year":"2006","unstructured":"Hironaka S, Zenda S, Boku N, Fukutomi A, Yoshino T, Onozawa Y (2006) Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer. Gastric Cancer 9:14\u201318. https:\/\/doi.org\/10.1007\/s10120-005-0351-6","journal-title":"Gastric Cancer"},{"key":"1076_CR21","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1056\/NEJMoa052985","volume":"354","author":"D Armstrong","year":"2006","unstructured":"Armstrong D, Bundy B, Wenzel L, Huang HQ, Baergen R, Shashikant L, Copeland LJ, Walker JL, Burger RA (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354:34\u201343. https:\/\/doi.org\/10.1056\/NEJMoa052985","journal-title":"N Engl J Med"},{"key":"1076_CR22","doi-asserted-by":"publisher","first-page":"209","DOI":"10.2147\/IJN.S41770","volume":"9","author":"N Gupta","year":"2014","unstructured":"Gupta N, Hatoum H, Dy GK (2014) First line treatment of advanced non-small-cell lung cancer - specific focus on albumin bound paclitaxel. Int J Nanomedicine 9:209\u2013221. https:\/\/doi.org\/10.2147\/IJN.S41770","journal-title":"Int J Nanomedicine"},{"key":"1076_CR23","doi-asserted-by":"publisher","first-page":"415","DOI":"10.2217\/17435889.2.4.415","volume":"2","author":"TE Stinchcombe","year":"2007","unstructured":"Stinchcombe TE (2007) Nanoparticle albumin-bound paclitaxel: a novel Cremphor-EL-free formulation of paclitaxel. Nanomedicine (Lond) 2:415\u2013423. https:\/\/doi.org\/10.2217\/17435889.2.4.415","journal-title":"Nanomedicine (Lond)"},{"key":"1076_CR24","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1200\/JCO.2011.39.5848","volume":"30","author":"MA Socinski","year":"2012","unstructured":"Socinski MA, Bondarenko I, Karaseva NA, Makhson AM, Vynnychenko I, Okamoto I, Hon JK, Hirsh V, Bhar P, Zhang H, Iglesias JL (2012) Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol 30:2055\u20132062. https:\/\/doi.org\/10.1200\/JCO.2011.39.5848","journal-title":"J Clin Oncol"},{"key":"1076_CR25","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3892\/or.2014.3210","volume":"32","author":"J Kinoshita","year":"2014","unstructured":"Kinoshita J, Fushida S, Tsukada T, Oyama K, Watanabe T, Shoji M, Okamoto K, Nakanuma S, Sakai S, Makino I, Furukawa H (2014) Comparative study of the antitumor activity of Nab-paclitaxel and intraperitoneal solvent-based paclitaxel regarding peritoneal metastasis in gastric cancer. Oncol Rep 32:89\u201396. https:\/\/doi.org\/10.3892\/or.2014.3210","journal-title":"Oncol Rep"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-021-01076-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-021-01076-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-021-01076-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T05:06:03Z","timestamp":1678511163000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-021-01076-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,5]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["1076"],"URL":"https:\/\/doi.org\/10.1007\/s10637-021-01076-8","relation":{"references":[{"id-type":"uri","id":"","asserted-by":"subject"}]},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,5]]},"assertion":[{"value":"18 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Tamiya M. reports grants and personal fees from Boehringer Ingelheim, grants and personal fees from Bristol-Myers Squibb, grants and personal fees from Ono Pharmaceutical, personal fees from MSD, personal fees from AstraZeneca, personal fees from Taiho Pharmaceutical, personal fees from Eli Lilly, personal fees from Asahi Kasei Pharmaceutical, personal fees from Chugai Pharmaceutical, outside the submitted work. Tamiya A. reports personal fees from Chugai Pharmaceutical, grants and personal fees from AstraZeneka, personal fees from Eli Lilly, personal fees from Boehringer Ingelheim, grants and personal fees from Ono Pharmaceutical, grants and personal fees from Bristol-Myers Squibb, personal fees from MSD, personal fees from Taiho, personal fees from Pfizer, personal fees from Kissei, outside the submitted work. Taniguchi Y. reports personal fees from Chugai Pharmaceutical, grants and personal fees from Bristol-Myers Squibb, grants and personal fees from Ono Pharmaceutical, personal fees from Boehringer Ingelheim, personal fees from MSD, personal fees from AstraZeneca, personal fees from Mundipharma, personal fees from Taiho Pharmaceutical, outside the submitted work. Kumagai T. reports grants and personal fees from Ono Pharmaceutical, grants and personal fees from MSD, grants and personal fees from AstraZeneca, grants and personal fees from Takeda Pharmaceutical, grants and personal fees from Taiho Pharmaceutical, grants and personal fees from Eli Lilly, grants and personal fees from Novartis Pharmaceutical, grants from Merck Serono, grants from Pfizer, grants from Boehringer lngelheim, personal fees from Teijin Pharmaceutical, grants and personal fees from Bristol-Myers Squibb, grants and personal fees from Chugai Pharmaceutical, outside the submitted work. Atagi A. reports grants and personal fees from AstraZeneca, grants and non-financial support from F. Hoffmann-La Roche, grants and personal fees from Ono Phermaceutical, grants and personal fees from Taiho Phermaceutical, grants and personal fees from Boehringer Ingelheim, grants and personal fees from Pfizer, grants and personal fees from Bristol-Myers Squibb, personal fees from Hisamitsu, grants and personal fees from MSD, grants and personal fees from Eli Lilly, personal fees from Kyowa Hakko Kirin, grants and personal fees from Merck Serono, grants and personal fees from Chugai Phermaceutical, outside the submitted work. Suzuki H, Katayama K, Minomo S, Nakao K, Takeuchi N, Matsuda Y, Naito Y, Shiroyama T, Okamoto N, Okishio K, Imamura F, Hirashima T has nothing to disclose.\u00a0","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Institutional review board (IRB) approval for this study was obtained from the Medical Research Ethics Committee of Osaka International Cancer Institute, Osaka Habikino Medical Center, and Kinki-Chuo Chest Medical Center (Osaka International Cancer Institute: No.1,609,019,097, Osaka Habikino Medical Center: No.662, Kinki-Chuo Chest Medical Center: No.460). We got written informed consent before study-specific procedures from all patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"All patients provided written informed consent for publication before enrollment.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}